Search for Current Clinical Trials

Study Name Description Trial Category Trial SubCategory
LUNGMAP This is a screening study to eavluate biomarker-driven therapies and immunotherapies in previously treated Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with Stage 4 or recurrent NSCLC. Tissue is sent for screening and patient can be assigned to a sub study based on mutations found. Cancer Metastatic Non-Small Cell Lung
NRG-GI004 The purpose of this study is to look at the effectiveness of Atezolizumab alone or in combination with other chemo regimens. You must be diagnosed with metastatic colorectal cancer with a DNA mismatch repair deficiency and BRAF gene mutation. Cancer Metastatic Colorectal
NRG-GI005 The purpose of this study is to look at the tumor DNA with blood draws to determine risk of cancer recurrance. You must be diagnosed with Stage 2A colon cancer. Cancer Colon
NRG-GY019 The purpose of this study is to compare paclitaxel, carboplatin and maintenace letrozole vs letrozole alone. You must be diagnosed with Stage 2-4 serous ovarian cancer. Cancer Serous Ovarian
NRG-HN005 The purpose of this study is to determine if a reduced dose of radiation therapy is as effective as the standard dose of radiation. You must be diagnosed with P16-Positive Oropharyngeal cancer. Your smoking history must be <10 pack-years. Cancer Oropharyngeal
NRG-LU002 The purpose of this study is to compare the effectiveness of chemo alone vs SBRT (stereotactic body radiation therapy) and chemo. You must be diagnosed with metastatic non-small cell lung cancer (NSCLC). You must have already received first line therapy. Cancer Metastatic Non-Small Cell Lung
NRG-LU007 This study is comparing effectiveness of atezolizumab alone vs atezolizumab and radiation. You must be diagnosed with extensive stage small cell lung cancer. Cancer Small Cell Lung
NSABP FB-12 This is a study for patients diagnosed with Her2 negative breast cancer. It is looking at the effectiveness and safety of doxorubicin plus cyclophosphamide followed by weekly paclitaxel plus trastuzumab and pertuzumab before surgery. Cancer Breast
PFO Occulder (PAS) The purpose of this research study is to evaluate the commercially available AmplatzerTM PFO Occluder and AmplatzerTM TalismanTM PFO Occluder in preventing another stroke by closing patients patent foramen ovale (PFO). Heart & Vascular Structural Heart Disease
Portico NG This is a study of an updated Portico Valve for TAVR. Heart & Vascular Structural Heart Disease
S1608 This study is for patients who have failed to achieve a complete remission or have relapsed within 2 years after completing treatment. You must have been diagnosed with follicular lymphoma grade 1, 2, or 3. Cancer Follicular Lymphoma
S1703 This study is looking at overall survival or patients monitored with serum tumor markers veruss usual care. You must be diagnosed with metastatic hormone receptor positive breast cancer. Cancer Metastatic Breast
S1706 This study is looking at using Olaparib after a masectomy at the same time as radiation vs getting radiation alone to determine if adding the medication provides better results. Cancer Breast
S1806 The purpose to this study is to look at the effectiveness of adding atezolizumab to chemo and radiation. You must be diagnosed with muscle invasive bladder cancer. You cannot have already received chemo or radiation. Cancer Bladder
Sync AV This is a new CRT with optimization turned on or off. Heart & Vascular Cardiac Arrhythmia
A151216 (ALCHEMIST) The purpose of this study is to send tissue for screening of mutations to find targeted therapy for your cancer. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). Cancer Non-Small Cell Lung
Agendia FLEX The purpose of this study is to create a large population based database to identify new gene associations in breast cancer. You must be diagnosed with stage 1, 2 or 3 breast cancer. A report is created that looks at the risk of your cancer spreading over the next 10 years. Cancer Breast
EA6141 The purpose of this study is to compare the effectiveness of Nivolumab, Ipilimumab and Sargramostim vs Nivolumab and Ipilmumab. You must be diagnosed with unresectable stage 3 or stage 4 melanoma. Cancer Melanoma
TAPUR The purpose of this study is find targeted treatment for patients with advanced cancer that has a actionable genomic variant revealed by genomic testing. Tissue from your cancer must be sent for genomic screening. You must have an advanced solid tumor, mulitple myeloma or B cell non-Hodgkin lymphona for which standard treatment options are no longer available. Cancer All tumor types